Novo Nordisk Reports STEER Real-World Study Data on Wegovy for Obesity and Cardiovascular Disease

Shots:

• The STEER real-world study data assessed the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide 2.4mg) vs tirzepatide among overweight or obese pts with CVD, but no diabetes in the US
• Study showed that continuous treatment (>30 days no gap) with Wegovy reduced risk of heart attack, stroke, CV or all-cause death by 57% vs tirzepatide, with 15 (0.1%) vs 39 (0.4%) events over 3.8 vs 4.3mos. average follow-up
• In all treated pts, regardless of treatment gaps, Wegovy reduced the risk of heart attack, stroke & all-cause death by 29% vs tirzepatide, with fewer CV events observed over 8.3 vs 8.6mos. average follow-up

Ref: Novo Nordisk | Image: Novo Nordisk | Press Release

Related News:- Novo Nordisk Reports the Health Canada’s Approval of Ozempic to Reduce Risk of Kidney Disease Progression & Cardiovascular Death in T2D & CKD Adults

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com